It was reported RAF inhibitors with anti-SRC activity show improved anti-proliferative activities in BRAF-mutant melanoma cells.20 To assess whether AZ304 plays a role in blocking SRC tyrosine kinase activation, the effects of single and combined treatments on SRC and STAT3 phosphorylation were examined (Fig. 4c). This evidence concerns the gene SRC and melanoma.